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Background. There is currently no safe human challenge model of Mycobacterium tuberculosis infection to
enable proof-of-concept efﬁcacy evaluation of candidate vaccines against tuberculosis. In vivo antimycobacterial
immunity could be assessed using intradermal Mycobacterium bovis bacille Calmette-Gue ´rin (BCG) vaccination as
a surrogate for M. tuberculosis infection.
Methods. Healthy BCG-naive and BCG-vaccinated volunteers were challenged with intradermal BCG. BCG
load was quantiﬁed from skin biopsy specimens by polymerase chain reaction (PCR) and culture colony-forming
units. Cellular inﬁltrate was isolated by suction blisters and examined by ﬂow cytometry. Prechallenge immune
readouts were correlated with BCG load after challenge.
Results. In BCG-naive volunteers, live BCG was detected at the challenge site for up to 4 weeks and peaked at
2 weeks. Inﬁltration of mainly CD15
1 neutrophils was observed in blister ﬂuid. In previously BCG-vaccinated
individuals, PCR analysis of skin biopsy specimens reﬂected a degree of mycobacterial immunity. There was no
signiﬁcant correlation between BCG load after challenge and mycobacterial-speciﬁc memory T cells measured
before challenge by cultured enzyme-linked immunospot assay.
Conclusions. This novel experimental human challenge model provides a platform for the identiﬁcation of
correlates of antimycobacterial immunity and will greatly facilitate the rational down-selection of candidate
tuberculosis vaccines. Further evaluation of this model with BCG and new vaccine candidates is warranted.
The tuberculosis vaccine ﬁeld has had to rely on pre-
clinical animal challenge models of Mycobacterium tu-
berculosis infection or on the development of in vitro
models of M. tuberculosis killing as surrogate measures
of vaccine efﬁcacy [1]. However, it remains unknown
how predictive these are of human in vivo protection,
and the development of a relevant in vivo human
challenge model would be a signiﬁcant advancement for
the ﬁeld. The existence of human challenge models for
pathogens, such as malaria, inﬂuenza, dengue, and ty-
phoid, has greatlyfacilitatedvaccine development [2–5].
However, the ethical barriers to challenging humans
with virulent replicating mycobacteria have thus far
limited the development of a human M. tuberculosis
challenge model. Here, we introduce a novel in vivo
bacille Calmette-Gue ´rin (BCG) challenge model using
Mycobacterium bovis BCG vaccination as a surrogate for
M. tuberculosis infection, based on the hypothesis that
an effective vaccine against M. tuberculosis should also
reduce the replication of BCG. Published preclinical
studies support the hypothesis that vaccine-induced
suppression of a BCG challenge in small animals is
comparable to that of an M. tuberculosis challenge, and
the vaccine most commonly assessed in such chal-
lenge studies is BCG [6–8]. BCG is a feasible challenge
agent for human use: it is a safe replicating myco-
bacterium (with 99.95% sequence homology relative to
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immunocompetent animals and humans, and it is licensed for
human use.
We have recently demonstrated that live BCG persists in
murine skin for $4 weeks and that intradermal BCG vaccina-
tion consistently protects against an intradermal BCG challen-
gedan effect that is independent of vaccination dose, route, or
vaccination-challenge interval. We have also shown in the
mouse model that efﬁcacy of BCG vaccination against sub-
sequent intradermal BCG challenge is comparable to known
vaccine efﬁcacy against aerosol M. tuberculosis challenge, sup-
porting the relevance of a mycobacterial skin challenge to
an aerosol M. tuberculosis challenge [10].
We now describe the application of these preclinical ﬁndings
to a human BCG challenge model, in which the kinetics of BCG
were assessed in the skin of healthy BCG-naive volunteers. Few
studies have attempted to detect BCG at the vaccination site,
other than in the context of a suppurative lesion complicating
vaccination, and none have actually quantiﬁed the level of live
BCG at these sites [11]. Here, we show that live BCG persists in
human skin for up to 1 month and that there is a spectrum of
mycobacterial growth or protection within a group with prior
BCG vaccination, which may reﬂect the spectrum of protection
conferred by BCG against tuberculosis in humans [12]. This
BCG challenge model has the potential to enable proof-of-
concept vaccine efﬁcacy screening for the ﬁrst time in humans
and to allow the identiﬁcation of an immunological proﬁle as-
sociated with reduced bacterial load in the skin.
METHODS
Recruitment and Enrollment
This study was approved by Oxfordshire Research Ethics
Committee A (REC reference 07/Q1604/3). All volunteers gave
written informed consent before participation. Twenty-eight
healthy, BCG-naive volunteers were recruited, followed by an
additional 12 participants previously vaccinated with BCG. For
this previously vaccinated group, volunteers were excluded if
they had received the BCG vaccine within the past 2 months;
however, the minimum period (from prior vaccination to re-
cruitment) of those enrolled was 8 months. The full inclusion
and exclusion criteria are described in Supplemental Methods 1.
All enrolled volunteers had normal baseline hematology and
biochemistry ﬁndings and negative results of hepatitis B and C
and HIV antibody testing. Latent M. tuberculosis infection was
excluded by ex vivo enzyme-linked immunospot (ELISPOT)
responses to ESAT6 and CFP10, as described elsewhere [13].
Challenge and Follow-up
The ﬁrst 28 participants were challenged intradermally with
BCG (SSI; 0.05 mL; diluted in saline to 0.1 mL) from a vial
containing 2–8 3 10
6 colony-forming units (CFU)/mL, giving
a ﬁnaldoseof approximately 1–4 3 10
5 CFU intothe upper arm
(deltoid insertion). The dose administered was conﬁrmed by
plating the BCG onto 7H11 Middlebrook agar. A punch biopsy
was performed at the challenge site 1, 2, or 4 weeks after
challenge. The 12 BCG-vaccinated volunteers were challenged
with BCG and underwent biopsy 2 weeks after challenge. After
vaccination, all 40 volunteers were followed up at weeks 1, 2, 4,
8, 12, and 24. Vaccination sites were assessed for local reactions
and vital signs recorded; 60 mL of blood was taken at each
time, and peripheral blood mononuclear cells and serum were
isolated and cryopreserved.
Skin Biopsies
The punch biopsy was performed using a sterile technique
with a standard 4-mm punch biopsy (Stiefel); 0.5–2 mL of
1% lignocaine with 1:200000 adrenaline was inﬁltrated
subcutaneously. The punch biopsy specimen was taken from
the center of the BCG vaccination site and frozen in liquid
nitrogen. Biopsy specimens were later thawed, weighed, and
homogenized in 1 mL of sterile phosphate-buffered saline
in a Dispomix machine (Thistle Scientiﬁc) before plating and
DNA extraction.
Culture, DNA Extraction, and Quantitative Polymerase Chain
Reaction
Culture of BCG, BCG DNA extraction from skin biopsy
specimens, and quantitative polymerase chain reaction (PCR)
were performed as described elsewhere [10]. Estimated CFU
counts were corrected for the total amount of DNA extracted
per biopsy specimen.
Creation of Suction Blisters
Suction blisters were created using an Eschmann suction unit
device (Reed et al [14]). Blisters were dressed and left overnight,
and the ﬂuid was harvested using a needle and syringe. Leu-
kocytes were isolated and stained for surface cellular markers
(Supplemental Methods 2).
Cultured ELISPOT Assays
Cultured ELISPOT assays were performed using frozen pe-
ripheral blood mononuclear cells as described elsewhere [15],
with some minor modiﬁcations, as follows: 1 3 10
6 cells/mL/
well were cultured in a 12-well plate in fetal calf serum–free
medium (AIM-V; Gibco). Cells were stimulated with 2 lg/mL
Ag85A (7 peptide pools), 1 lg/mL TB10.3 (1 peptide pool), and
10 lL/mL recombinant human interleukin 7 and incubated for
3 days. A total of 20 U/mL recombinant human interleukin 2
and 10 lL/mL interleukin 7 were added to each well on day 3,
and 20 U/mL interleukin 2 was added on days 7 and 10 in
0.5 mL of fresh medium. On day 12, the cells were washed in
fresh medium, rested overnight, washed, counted, and plated at
0.3 3 10
6 or 0.1 3 10
6 cells/well in an ELISPOT assay. Results
are expressed as spot forming cells per 1 million cells at day 0.
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Data were not normally distributed. Consequently, medians
with interquartile ranges are presented, and nonparametric tests
have been applied. Differences in BCG CFU counts between
groups were analyzed using the Kruskal-Wallis test (for
comparison of .2 independent groups) and Mann–Whitney
test (for comparison of 2 groups). Correlations (within in-
dividuals) were analyzed by Spearman rank. The statistical
software used was Stata (StataCorp). Differences were con-
sidered statistically signiﬁcant at P , .05 (*P , .05, **P , .01,
and ***P , .001).
RESULTS
Safety and Tolerability of BCG Challenge Model
Twenty-eight BCG-naive and 12 previously BCG-vaccinated
volunteers were challenged with BCG intradermally. Skin bi-
opsy specimens were taken from the center of the challenge
site of naive volunteers 1, 2, or 4 weeks after challenge. Biopsy
specimens were taken 2 weeks after challenge in the previously
BCG-vaccinated group. There were no unexpected local re-
actions or systemic complications after BCG challenge. Three
of 28 volunteers in the BCG-naive group and all 12 in the
Figure 1. Quantification of bacille Calmette-Gue ´rin (BCG) in skin biopsy specimens from BCG challenge sites. A, Appearance of skin 2 weeks after
biopsy. B, Estimated number of BCG copies (log10) per biopsy specimen (taken at 1, 2, or 4 weeks after challenge) by quantitative polymerase chain
reaction (PCR) (corrected for nanograms of DNA extracted). C, Colony-forming unit (CFU) counts after 3–4 weeks of incubation on 7H11 Middlebrook agar.
Bars represent median per group. D, Correlation between CFU counts measured by culture and PCR 1, 2, and 4 weeks after challenge (Spearman rank,
week 1, R 52 0.22, P 5 .6 [left]; week 2, R 5 0.77, P 5 .004 [middle]; week 4, R 5 0.75, P 5 .03 [right]). E, Appearance of blister at 1 week after
challenge. F, Application of CD45 marker to blister cells, compared with side scatter (SSC).
Human BCG Challenge Model d JID 2012:205 (1 April) d 1037BCG-vaccinated group developed purulent discharge from
the challenge site 1–2 weeks after vaccination, but all cases
spontaneously subsided within 2–4 weeks. Punch biopsies
healed well and left a small scar superimposed on the chal-
lenge site.
Detection of Live BCG in Human Skin After Vaccination
BCG was detected in punch biopsy specimens (Figure 1A)f r o m
all 28 BCG-naive volunteers by PCR (Figure 1B) and from 19 of
28 by culture (Figure 1C). Live BCG was detected by culture up
to 2 weeks in 10 of 12 volunteers and up to 4 weeks in 4 of 8
(Figure1C).Therewasadecreaseingenomecopies,asidentiﬁed
by PCR, during weeks 1–2 but not in CFU counts, and there was
considerablevariability intheculture data, upto 3 logsatweek 4
(Figure 1C). Although this makes it more difﬁcult to show
a statistically signiﬁcant difference between time points, there
remained a trend for a reduction in live BCG in the skin over
time. Quantiﬁcation of BCG by PCR was a mean of 1 log higher
than by culture.
Local Cellular Profile at BCG Vaccination Site
Blister cells were isolated 1 week after BCG vaccination
(Figure 1E), and surface staining revealed distinct populations




1 cells (Figure 1F),
with a relative predominance of CD15
1 cells. A signiﬁcant
unknown CD45
1 population (with a small proportion cos-
taining for CD14 and CD15) remained to be fully characterized.
Direct inspection of the cellular types by direct microscopy of
formalin sections conﬁrmed the cellular populations identiﬁed
by ﬂow cytometry and conﬁrmed that there were almost no
platelets. There were very small numbers of CD1a
1 dendritic
cells and CD56
1 natural killer cells (data not shown).
Comparison of Challenge Results: PCR vs Culture CFU Counts
The PCR and culture data for the group with prior BCG vac-
cination are shown in Figure 2A. Within this group, there
was a strong correlation between the 2 methods of bacterial
quantiﬁcation 2 weeks after challenge (R 5 0.87; P 5 .0002)
Figure 2. Variability in postchallenge colony-forming unit (CFU) counts in bacille Calmette-Gue ´rin (BCG)–vaccinated humans. A, Comparison between
culture and polymerase chain reaction (PCR) challenge results in BCG-vaccinated volunteers, log scale. B, Correlation between culture (CFU count) and
PCR (Spearman rank). Comparison of PCR and culture challenge results in naive (NAIVE–BCG) and BCG-vaccinated (BCG1–BCG2) volunteers. C, PCR
values (BCG copies [log10] per biopsy specimen, corrected for nanograms of DNA extracted) in BCG-naive and BCG-vaccinated groups. D, Corresponding
culture values (log10 BCG CFU count per biopsy specimen). Exact P values are shown.
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sponding BCG-naive group (R 5 0.77; P 5 .004).
A comparison of the 2-week postchallenge CFU counts be-
tween the BCG-vaccinated and BCG- naive groups is shown in
Figure 2C and 2D. The PCR results (Figure 2C) suggest that the
immunity conferred by prior BCG vaccination can protect
against a challenge dose by 1l o gC F U( P 5 .02 with correction
forthe totalDNAextracted).However,theculturedatawere not
supportive of the PCR ﬁndings in detecting a difference between
naive and vaccinated groups (Figure 2D).
Associations Between Prechallenge Immune Parameters and
Challenge CFU Counts
The T-helper 1 cytokine interferon (IFN) c is essential but not
sufﬁcient for protective immunity against M. tuberculosis [1].
Ex vivo IFN-c ELISPOT assays to measure effector T-cell re-
sponses against BCG-immunodominant antigens, TB10.3,
and antigen 85A were thus evaluated before BCG challenge.
However, these responses did not correlate with the CFU
data (BCG naive, R 52 0.1 and P 5 .8; BCG vaccinated,
R 52 0.25 and P 5 .5; data not shown). There was a trend
for a negative correlation between prechallenge cultured
ELISPOT responses against the same antigens (which meas-
ures central memory T-cell responses [16]) and CFU count
after challenge, although this did not reach statistical sig-
niﬁcance (R 52 0.4; P 5 .2) (Figure 3C). The cultured
ELISPOT responses in BCG-naive volunteers were uni-
formly low (Figure 3B). There was no correlation between
time since BCG vaccination and cultured ELISPOT responses
(Figure 3D).
Figure 3. Prechallenge cultured enzyme-linked immunospot (ELISPOT) responses in bacille Calmette-Gue ´rin (BCG)–vaccinated volunteers. Graphs show
the responses per million original cultured cells, measured at day 0 (total culture period, 13 days). Combined cultured interferon c T-cell responses to
TB10.3 and 85A peptide pools are shown for each volunteer. Volunteers in order of increasing challenge colony-forming unit (CFU) count are shown along
the x-axis, labeled by exact counts per biopsy specimen. Prechallenge responses are shown for BCG-vaccinated volunteers (n 5 12) (A) and BCG-naive
volunteers (n 5 4, B); there were only enough frozen peripheral blood mononuclear cells for 4 of the naive volunteers to allow processing of cultured
ELISPOT assays. C, Correlation between magnitude of memory T-cell response and bacterial load of challenge (BCG CFU count per biopsy specimen;
R 52 0.4, P 5 .2). D, Time since prior BCG vaccination versus magnitude of prechallenge cultured ELISPOT responses.
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Here, we have presented a novel BCG challenge model for the
assessment of mycobacterial immunity and candidate tubercu-
losis vaccine efﬁcacy testing and down-selection.
To our knowledge, this is the ﬁrst reported clinical study
undertaken to evaluate the feasibility of such a challenge
model, although another study used similar methodology for
a different purpose [11]. In that study, serial punch biopsy
specimens were taken immediately adjacent to (not from the
center of) the BCG vaccination site to detect nonquantitative
mycobacterial shedding. At 1 month, swab cultures from
drainage vaccine ulcerations in 5 volunteers detected viable
BCG; however, PCR analyses of biopsy specimens did not de-
tect BCG in 4 of 7 volunteers [11]. In comparison, in the vol-
unteers participating in the study reported here, a larger, 4-mm
biopsy specimen was obtained once, at the center of the chal-
lenge site, to detect and quantify the majority of the total BCG
present, and BCG was detected by PCR in all 28 volunteers.
Obtaining standard-size central biopsy specimens also allowed
comparison of the levels of BCG detected between groups,
giving an indication of the peak time for BCG detection.
The data from the pilot study in BCG-naive individuals
suggested that week 2 after challenge was the most suitable time
to enable an observable difference in BCG replication between
vaccinated and control groups; at this time, the highest median
CFU count was observed with the least variability. The vari-
ability probably reﬂects, in part, the genetic diversity and dif-
ferential environmental mycobacterial exposure of volunteers
and the limited sample size. The level of BCG in the skin at
4 weeks was both too low and too variable to enable a signiﬁcant
difference between a control and a vaccinated group to be
observed, and the week 1 time-point may have only allowed
assessment of innate immune processes in control of BCG
replication, rather than true vaccine-induced adaptive immu-
nity. Similar results have been observed in preclinical studies: at
14 days after challenge, a clear difference in M. tuberculosis CFU
count was seen in the lungs of M. tuberculosis–infected naive
mice, compared with BCG-vaccinated mice [17], and a signiﬁ-
cantdifference inBCG CFUcountwas seen inthe lungs andears
of BCG-challenged naive mice, compared with BCG-vacci-
nated mice [10]. In light of these data, the week 2 time-point
was chosen for the punch biopsy in the second part of the
study, which involved volunteers who had been previously
vaccinated with BCG. The 1-log discrepancy between CFU
counts by PCR and culture may reﬂect a failure of PCR to
distinguish between live and dead mycobacteria and would
explain the weak PCR and culture correlation at the early week
1 time-point (and the discrepancy in values), compared with the
signiﬁcant positive correlation at later time-points (Figure 1D).
The PCR results (Figure 2C) suggest that the immunity
conferred by prior BCG vaccination can protect against
a challenge dose by 1l o gC F U( P 5 .02 when corrected for the
total DNA extracted). This level of protection is comparable to
that seen in the murine model [6–8]. However, the culture data
werenotsupportiveofthe PCRﬁndingsindetecting adifference
between the naive and vaccinated groups (Figure 2D). It is
possible that the PCR assay overestimated the protective effect
of BCG, by detecting dead and live BCG in the naive group (as
discussed above). Alternatively, the difference seen by PCR may
be real, because agar plating of the biopsy specimens from the
2 groups was done separately in real time at the end of the study
period for each group. Unlike this CFU count analysis, which
could only be done once because of sample availability, PCR
of extracted DNA was performed for both groups in parallel
in the same assay at the end of the study period for the
second group. Therefore, it is likely that the CFU data are
less directly and less reliably comparable between the groups
than the PCR data.
In addition, because volunteers were recruited sequentially
over a 2-year period for the naive groups of the study, it was not
logistically possible to vaccinate all volunteers with the same
batch of BCG, and there was a 1-log CFU count variability
between some of the batches. However, there was no correlation
between the number of CFUs administered and the CFU count
at the biopsy site 2 weeks later (R 5 0.15; P 5 .65, by Spearman
rank). This is reassuring, because the outcome measure was
independent of the amount of BCG administered.
A repeat controlled study, with parallel administration of
the same batch of BCG, is required to conﬁrm and validate the
ﬁndings of this pilot proof-of-concept study. Nevertheless, the
PCR data suggest a degree of antimycobacterial immunity in
the previouslyBCG-vaccinatedgroup.Similarly,analysisofboth
groups by PCR and culture showed a spread of challenge BCG
load. This is likelyto reﬂect a spread of human immunity because
of (1) variable effects of prior BCG vaccination, (2) differential
exposure to nontuberculous mycobacteria, and (3) genetic dif-
ferences in innate and adaptive immunity.
The range of challenge CFU counts in the BCG-vaccinated
group suggests there is potential within this model for the
identiﬁcation of immunological correlates of protection. The
levelofdetectableCFUcountsinthe BCG-vaccinatedgroupalso
allows for the evaluation of BCG booster vaccines. This is es-
sential for application of this model to tuberculosis vaccine
testing, in which showing improvement over BCG is necessary
and has often been difﬁcult in preclinical models, in particular,
the guinea pig model [18]. If BCG is shown in subsequent hu-
man studies to protect against a BCG skin challenge, a similar
study in a country with higher endemic mycobacterial exposure
would be important to investigate whether the protective effect
of BCG on a skin challenge is reduced in persons who have been
environmentally primed. If this was observed, it would further
support the relevance of an intradermal challenge model. The
evaluation of BCG replication in a no-vaccine control group
1040 d JID 2012:205 (1 April) d Minassian et alwould also be important to evaluate whether such a model has
use in areas where tuberculosis is endemic.
BCG survival in a skin lesion may not necessarily reﬂect
pathogenic survival in the lungs, because the immune envi-
ronments of skin and lung are different and this could have
a differential impact on bacterial survival. Of importance, we
previously compared the effect of BCG with intradermal
(skin) and intranasal (lung) challenge in parallel and found
highly comparable results [10]. This supports the relevance
of a myocbacterial intradermal (skin) challenge to an aerosol
M. tuberculosis challenge. Nevertheless, the ear represents
a comparatively different immune compartment, with rela-
tively fewer lymphoid cells, and there is likely to be a balance in
the level of bacterial replication and clearance in the ear, with
the clearance attributable to either bacterial death and phago-
cytic clearance or phagocytic transport or draining of live
bacteria to the local draining lymph nodes. Indeed, the
abundant CD15
1 neutrophil population observed in blister
ﬂuid (Figure 1F) is consistent with data from animal models
of intradermal BCG infection in which neutrophils were
shown to be induced by BCG in the skin and engineer the
induction of T cells through their interactions with dendritic
cells [19, 20].
Although there is no guarantee that protection against an
attenuated BCG strain in humans will predict protection against
av i r u l e n tM. tuberculosis strain, the evidence from preclinical
models is, however, supportive of this prediction. As shown
in our murine BCG challenge model [10], the protective effect
of intradermal BCG on both intradermal and intranasal BCG
challenges mirrors the effect of parenteral BCG on M. tubercu-
losis aerosol challenge in multiple previous studies published by
many different research groups during the past 30 years. These
data suggest that, if a BCG-based vaccine regimen is protective
against aerosol M. tuberculosis, its effect against a BCG skin
challenge would predict its effect on an aerosol M. tuberculosis
challenge. Further experimental validation of the relevance of
this BCG challenge model to M. tuberculosis is planned in the
more relevant cattle and nonhuman primate preclinical ani-
mal models, in parallel with the establishment of this model in
humans.
Ex vivoIFN-c ELISPOTresponsestoBCG-immunodominant
antigens did not correlate with the challenge CFU count. This
assay measures circulating effector and effector memory T-cell
responses, and these results are in agreement with recent
studies of viral and parasitic infections in mice and humans
that have shown central memory responses to correlate with
pathogen clearance and protection [16, 21, 22]. Tuberculosis
vaccine studies in cattle have also demonstrated the impor-
tance of the central memory T-cell response, as measured by
cultured ELISPOT assay, in correlating with protective efﬁ-
cacy against M. bovis challenge [23, 24]. Data from this clinical
study showed a trend for prechallenge cultured ELISPOT
responses to negatively correlate with CFU count after chal-
lenge, although this did not reach statistical signiﬁcance.
Larger controlled studies are underway to validate these pre-
liminary ﬁndings.
This study has demonstrated the feasibility of developing
a challenge model to assess mycobacterial vaccines in humans.
Validation of an intradermal BCG challenge as a surrogate for
aerosol M. tuberculosis infection is planned in large preclinical
animal models, and results from this human challenge will need
validating against ﬁeld efﬁcacy trials. However, the standardi-
zation of microbial challenge models has been essential to the
development of vaccines for other diseases [25], and thus, this
approach now promises to also allow such cost-effective,
small-scale, phase IIa vaccine efﬁcacy trials to be undertaken
for tuberculosis.
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